These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 16966690

  • 1. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H.
    J Clin Oncol; 2006 Oct 10; 24(29):4721-30. PubMed ID: 16966690
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.
    Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H.
    Cancer Gene Ther; 2009 Aug 10; 16(8):620-4. PubMed ID: 19287371
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER.
    J Clin Oncol; 2004 Jul 15; 22(14):2800-7. PubMed ID: 15254047
    [Abstract] [Full Text] [Related]

  • 4. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, González Dueñas M, Viada C, García Verdecia B, Crombet Ramos T, González Marinello G, Lage Dávila A.
    J Clin Oncol; 2008 Mar 20; 26(9):1452-8. PubMed ID: 18349395
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M.
    J Clin Oncol; 2005 Sep 20; 23(27):6674-81. PubMed ID: 16170175
    [Abstract] [Full Text] [Related]

  • 6. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ.
    J Clin Oncol; 2008 Sep 20; 26(27):4418-25. PubMed ID: 18802154
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma.
    Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL.
    Cancer Gene Ther; 2006 Dec 20; 13(12):1052-60. PubMed ID: 16826191
    [Abstract] [Full Text] [Related]

  • 8. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER.
    Cancer Gene Ther; 2003 Nov 20; 10(11):850-8. PubMed ID: 14605671
    [Abstract] [Full Text] [Related]

  • 9. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
    O'Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, Ryan C, Priest K, Bromelow KV, Palmer RD, Tuckwell N, Kennard DA, Souberbielle BE.
    Br J Cancer; 2000 Oct 20; 83(7):853-7. PubMed ID: 10970684
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
    Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J.
    Clin Cancer Res; 2011 Jan 01; 17(1):183-92. PubMed ID: 21208907
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
    Vokes EE, Figlin R, Hochster H, Lotze M, Rybak ME.
    Cancer J Sci Am; 1998 Jan 01; 4(1):46-51. PubMed ID: 9467046
    [Abstract] [Full Text] [Related]

  • 12. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
    Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H.
    Eur J Cancer; 2015 Nov 01; 51(16):2321-9. PubMed ID: 26283035
    [Abstract] [Full Text] [Related]

  • 13. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T.
    J Immunol; 2009 Feb 15; 182(4):2492-501. PubMed ID: 19201905
    [Abstract] [Full Text] [Related]

  • 14. Autologous dendritic cell vaccines for non-small-cell lung cancer.
    Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J.
    J Clin Oncol; 2004 Jul 15; 22(14):2808-15. PubMed ID: 15254048
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ.
    J Immunother; 2008 Jan 15; 31(1):72-80. PubMed ID: 18157014
    [Abstract] [Full Text] [Related]

  • 16. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R, Butts C.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [Abstract] [Full Text] [Related]

  • 17. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D.
    J Clin Oncol; 2007 Jul 01; 25(19):2727-34. PubMed ID: 17602077
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH, Kübler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ, Gansbacher B.
    J Gene Med; 2007 Jul 01; 9(7):547-60. PubMed ID: 17514769
    [Abstract] [Full Text] [Related]

  • 19. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
    Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D.
    Clin Lung Cancer; 2010 Nov 01; 11(6):391-5. PubMed ID: 21071331
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD.
    Clin Cancer Res; 2005 Aug 01; 11(15):5515-25. PubMed ID: 16061868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.